Skip to main content
LCTX logo

LCTX · Lineage Cell Therapeutics, Inc. · Investor Relations

Track LCTX — free
$0.77 -0.05 (-5.87%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$195.26M
Shares
252.95M
Volume · Nov 20 2.04M Avg daily vol (3M) 1.63M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-12 Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Acquired NeuroAirmid Therapeutics, Inc. and Its Cell Therapy Product Candidate for Huntington’s Disease, Currently Enrolling in a Phase 1b/2a Clinical Trial (REGEN4HD) Announced Issuance of a Patent Covering its AlloSCOPE™ “5D” Technology, a Component of Its AlloSCOPE Cell Manufacturing Platform

2026-11-12 Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s Disease

Human Neural Stem Cell Transplants Offer a Novel Approach to Treating Huntington’s Disease Acquisition Includes Rights Relating to a Stem Cell-Derived Clinical Trial for Huntington’s Disease (REGEN4HD), a Phase 1b/2a Clinical Trial Currently Enrolling Patients NeuroAirmid Shareholders Received $4.7

2026-11-05 Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026

CARLSBAD, Calif. --(BUSINESS WIRE)--Nov. 5, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its third quarter 2026

2026-10-29 Lineage Provides Update on ReSonance® Program for Hearing Loss

Advanced Collaboration with WDI for ReSonance (ANP1) Program Into Second Year: All Preclinical Development Activities Planned For Year 1 of Collaboration Successfully Achieved Danish Medicines Agency (DKMA) Meeting Scheduled in Q4 2026 to Discuss ReSonance Development Plans and Seek Scientific

2026-09-08 Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform

U.S. Patent No. 12,692,476 Has an Expected Expiration Date of June 9, 2043 CARLSBAD, Calif. --(BUSINESS WIRE)--Sep. 8, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for

2026-08-06 Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Announced Progress with Wholly-Owned Corneal Endothelial Disease Cell Therapy Program (COR1) Established Scientific Advisory Board With Cell Therapy Executive Joachim Fruebis, PhD

2026-07-30 Lineage Cell Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026

CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 30, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel, allogeneic, “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its second

2026-07-13 Lineage Provides Update on COR1 Cell Therapy Program for Corneal Endothelial Disease

Company Will Host Conference Call Today at 4:30 PM ET / 1:30 PM PT COR1 Aims to Provide an “Off the Shelf” Supply of Allogeneic CEnCs for Patients Suffering from Corneal Endothelial Disease Utilizes the Company’s AlloSCOPE™ 5D Manufacturing Process, Featuring Seamless, Bioreactor-based Expansion

2026-07-06 Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 6, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that Brian M.

2026-05-12 Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Positive 3 Year Phase 1/2a Clinical Data of RG6501 (OpRegen®) Featured at Retinal Therapeutics Innovation Summit 2026 Launched New Corneal Endothelial Disease Cell Therapy Program Met First Milestone with AlloSCOPE™ 5D Manufacturing Initiative Treated Second Chronic SCI Patient in OPC1 DOSED Device

2026-05-05 Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

CARLSBAD, Calif. --(BUSINESS WIRE)--May 5, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing “off the shelf” allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026

2026-05-04 OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026

Gains in best corrected visual acuity (BCVA) of +9 letters at 36 months among patients with extensive coverage of OpRegen cell therapy to the geographic atrophy (GA) lesion site OCT imaging indicated partial restoration of outer retinal structure, re-appearance of an RPE layer, and features

2026-04-13 Lineage Announces Formation of Scientific Advisory Board

CARLSBAD, Calif. --(BUSINESS WIRE)--Apr. 13, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the formation of a Scientific

2026-03-24 Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

New Internally-Developed and Wholly-Owned Asset Benefits From Existing Ophthalmology and Manufacturing Expertise Fuchs Endothelial Corneal Dystrophy (FECD) Afflicts More Than 7.3% of the Population with a Predicted 10-Year CAGR of 7.7% CARLSBAD, Calif. --(BUSINESS WIRE)--Mar.

2026-03-05 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen ® Cell Therapy) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Achieved First Milestone Under Worldwide Collaboration with Genentech Based on RG6501 (OpRegen Cell Therapy) Program Manufacturing and Clinical Advancements

2026-02-26 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026

CARLSBAD, Calif. --(BUSINESS WIRE)--Feb. 26, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its fourth quarter

2026-01-06 Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience

CARLSBAD, Calif. --(BUSINESS WIRE)--Jan. 6, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today announced the receipt of a novel, induced

2026-01-05 Lineage Cell Therapeutics Issues Letter to Stockholders

CARLSBAD, Calif. --(BUSINESS WIRE)--Jan. 5, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today published a letter to shareholders

2025-11-24 Lineage Achieves First Milestone Under Worldwide Collaboration Agreement with Genentech

LINEAGE ACHIEVES FIRST MILESTONE UNDER WORLDWIDE COLLABORATION AGREEMENT WITH GENENTECH November 24, 2025 Lineage Cell Therapeutics, Inc. today announced it had achieved the first milestone available under its worldwide collaboration with Roche and Genentech , a member of the Roche Group, for

Past events

Source: https://investor.lineagecell.com/

Key facts CIK 876343 CUSIP 53566P109 13F (30d) 146 filings 122 filers Visit website Investor relations